There Are So Many Ways To Stop Covid-19 And Variants Besides Mandated Vaccines

  • There Are So Many Ways To Stop Covid-19 And Variants Besides Mandated Vaccines

  • TheRealRestoreInc.

    September 27, 2021 at 11:23 pm

    <div>Name the preventative compounds and treatments you know of to share with this Trial Site News Community</div><div>

    Here’s an example:

    1) Kefir.


    Kefir: A protective dietary supplementation against viral infection

    Abstract: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a recently discovered coronavirus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several scholars have tested antiviral drugs and compounds to overcome COVID-19. Kefir is a fermented milk drink similar to a thin yogurt that is made from kefir grains. Kefir and its probiotic contents can modulate the immune system to suppress infections from viruses (e.g., Zika, hepatitis C, influenza, rotaviruses). The antiviral mechanisms of kefir involve enhancement of macrophage production, increasing phagocytosis, boosting production of cluster of differentiation-positive (CD4(+)), CD8(+), immunoglobulin (Ig)G(+) and IgA(+) B cells, T cells, neutrophils, as well as cytokines (e.g., interleukin (IL)-2, IL-12, interferon gamma-). Kefir can act as an anti-inflammatory agent by reducing expression of IL-6, IL-1, TNF-, and interferon-. Hence, kefir might be a significant inhibitor of the cytokine storm that contributes to COVID-19. Here, we review several studies with a particular emphasis on the effect of kefir consumption and their microbial composition against viral infection, as well as discussing the further development of kefir as a protective supplementary dietary against SARS-CoV-2 infection via modulating the immune response.

    Published: 11/11/2020



  • Astragale

    September 29, 2021 at 3:30 pm

    Olive leaf: oleuropein, hydroxy tyrosol, verbascoside, apigenin-7-glucoside and luteolin-7-glucoside

    Standardized Olive Leaf Capsules; as a Co-therapy in the Treatment of COVID-19 Patients

    Starting from December 2019, novel coronavirus disease 2019 (COVID-19) pandemic has caused a tremendous economic loss and unprecedented health crisis across the globe. Discovering an effective and safe drug candidates for the treatment of COVID-19 and its associated symptoms became a global urgent demand especially due to limited data that have been released regarding the vaccine efficacy and safety in humans. Reviewing the recent research, Olive leaf was selected as a potential co-therapy supplement for the treatment and the improvement of clinical manifestations in COVID-19 patients. Olive leaves reported to be rich in phenolic compounds such as oleuropein, hydroxy tyrosol, verbascoside, apigenin-7-glucoside and luteolin-7-glucoside which has been reported as anti-SARS-CoV-2 metabolites in recent In silico, computational and in vitro studies. In addition, olive leaf extract was previously reported in several in vivo studies for its anti-inflammatory, analgesic, antipyretic, immunomodulatory and anti-thrombotic activities which is of a great benefit in the control of associated inflammatory cytokine storm and disseminated intravascular coagulation in COVID-19 patients.

    A placebo-controlled, randomized clinical trial at Fayoum University Hospital in Egypt will be conducted. RT-PCR confirmed COVID-19 adults showing mild to moderate disease will be enrolled in the study. Patients presenting with multi-organ failure, ventilator support, and chronic diseases (except diabetes mellitus and hypertension) were excluded. Patients were randomly assigned in 1:1 ratio to receive standardized olive leaves capsules (containing 20-50% oleuropein) or placebo up-to 10 days along with standard care. The expected outcomes included symptom alleviation, viral clearance, improvement of analysis (CBC, CRP, LDH, ESR, Ferritin, D-dimer, creatinine, ALT and AST) and a 30-day mortality in intention-to-treat population.

    May 7th 2021

Viewing 1 - 2 of 2 replies

Original Post
0 of 0 posts June 2018